Biotech Platform Technologies Make Big Promises
Source: George S. Mack, The Life Sciences Report  (2/28/12)
Words to Invest By: Make sure you see a lead development product that big pharma is willing to bet on. I love the idea of a smart technology platform that could feed multiple product candidates into a biotech pipeline. The notion is exhilarating because that's where those rare 10- and 20-baggers come from. . . More >

Biotech Stocks Start Strong in 2012: John McCamant
Source: George S. Mack of The Life Sciences Report  (2/23/12)
After a three-and-one-half year slide, biotechnology stocks started 2012 with a powerful move to the upside. Is this an arms-acquisition race for products in development, or is it about excellent fundamentals that are just getting noticed? Medical Technology Stock Letter Editor John McCamant sees a bit of both, and in this exclusive interview with The Life Sciences Report, he has selected a few names that he believes will rise to the top. More >

Infectious Disease Technologies Could Open Investment Opportunities in 2012: Stephen Dunn
Source: George S. Mack of The Life Sciences Report  (2/16/12)
Investors have avoided infectious disease companies like the plague, but LifeTech Capital President and Senior Managing Director of Research Stephen Dunn doesn't agree, and he has staked out some ideas in this space that could make you financially better off. In this exclusive interview with The Life Sciences Report, Dunn explains the rationale and delivers the names of bug-fighting companies that use the newest technologies to overcome old barriers to success. More >

Platform Technologies Promise Big Payoffs: Juan Sanchez
Source: George S. Mack of The Life Sciences Report  (2/10/12)
Platform technologies promise big payoffs because they offer the prospect of nearly unlimited assets that might be developed to combat disease, but they make investors very nervous because of their propensity to burn cash in a hurry. In this exclusive interview with The Life Sciences Report, Ladenburg Thalmann & Co. Vice President and Senior Analyst Juan Sanchez makes his case for a few companies that could produce numerous products from their technology-rich pipelines. More >

Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham
Source: George S. Mack of The Life Sciences Report   (1/31/12)
It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors. More >

Driving Value for Pharma and Biotech Companies: Insights from Biotech Showcase 2012
Source: The Life Sciences Report Editors  (1/20/12)
The 2012 Biotech Showcase investor conference in San Francisco drew a record number of life science interests from all over the world. More >

Five Biotechs to Consider: Mara Goldstein
Source: George S. Mack of The Life Sciences Report
The complexity of the mammalian immune system is daunting for molecular biologists and drug developers, but incremental progress has brought biotech and biopharma to the point where small molecules and biologics are being developed with some predictability and with some real successes. Clearly, the advantage of leveraging the immune system is that it can apply broadly to so many different systems, organs and disease indications ranging from mild skin disease to brain tumors. For a recent Life Sciences Report interview, I spoke with Cantor Fitzgerald & Co. Senior Biotechnology Analyst Mara Goldstein, who has chosen to follow companies developing immunotherapeutics to treat cancers. In a nutshell, she decided on immunotherapy because she believes it is underappreciated by investors, and she opted to follow oncology because the market is huge. More >